<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The variable pathogenesis and progressive nature of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> emphasise the need for new <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> treatments </plain></SENT>
<SENT sid="1" pm="."><plain>The long acting glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> and dipeptidyl peptidase-4 inhibitors have improved the treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Novel approaches include inhibitors of <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="105" ids="17234">glucose</z:chebi> co-transporter 2, which increase renal <z:chebi fb="105" ids="17234">glucose</z:chebi> elimination, G-protein-coupled receptor <z:chebi fb="4" ids="48705">agonists</z:chebi>, which potentiate insulin and incretin hormone secretion </plain></SENT>
<SENT sid="3" pm="."><plain>Proof of principle has been shown for glucagon receptor <z:chebi fb="4" ids="48705">agonists</z:chebi>, glucokinase activators and treatment with dual intestinal <z:chebi fb="7" ids="16670">peptides</z:chebi>, which <z:hpo ids='HP_0000001'>all</z:hpo> induce <z:hpo ids='HP_0001824'>weight loss</z:hpo> and improve <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance </plain></SENT>
</text></document>